autologous AML-DCs

**Autologous AML-DCs** are dendritic cell-based cancer immunotherapies manufactured by differentiating and maturing dendritic cells from a patient's own leukemic blasts. The process involves extracting blast cells from peripheral blood or bone marrow, then culturing them with growth factors (GM-CSF, IFN-α, IL-4, FLT3-L) to obtain immature dendritic cells, followed by maturation via pathogen-associated molecular patterns. These cells naturally present a wide repertoire of leukemia-associated antigens (LAAs, including WT1, PRAME, RHAMM, survivin, TERT) on their surface, potentially stimulating polyclonal T-cell responses against leukemic cells. Unlike conventional dendritic cell vaccines, AML-DCs do not require exogenous loading of antigens because they already express the full complement of AML antigens. The therapy is conceived to prevent or delay relapse in AML patients post-remission, especially those ineligible for stem cell transplantation. Clinical experience suggests that autologous AML-DCs can elicit both cytotoxic T-cell and helper T-cell responses, but durable clinical benefit has been limited. Challenges include lower immune activation compared to monocyte-derived dendritic cells and possible tolerogenic features (IDO-1 expression, lack of co-stimulatory ligands). Development strategies focus on improving immunogenicity and standardizing manufacturing[1][3][4][5][7].

Other names

autologous AML-DCAML-DCsautologous acute myeloid leukemia-derived dendritic cells